What is the official website of Gilead HIV ?

The official website of Gilead HIV is https://www.gileadhiv.com/.

What is Gilead HIV's cybersecurity risk score?

Gilead HIV has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Gilead HIV experienced?

According to Rankiteo, Gilead HIV currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Gilead HIV been affected by any supply chain cyber incidents ?

According to Rankiteo, Gilead HIV has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Gilead HIV have SOC 2 Type 1 certification ?

According to Rankiteo, Gilead HIV is not certified under SOC 2 Type 1.

Does Gilead HIV have SOC 2 Type 2 certification ?

According to Rankiteo, Gilead HIV does not hold a SOC 2 Type 2 certification.

Does Gilead HIV comply with GDPR ?

According to Rankiteo, Gilead HIV is not listed as GDPR compliant.

Does Gilead HIV have PCI DSS certification ?

According to Rankiteo, Gilead HIV does not currently maintain PCI DSS compliance.

Does Gilead HIV comply with HIPAA ?

According to Rankiteo, Gilead HIV is not compliant with HIPAA regulations.

Does Gilead HIV have ISO 27001 certification ?

According to Rankiteo,Gilead HIV is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Gilead HIV operate in ?

Gilead HIV operates primarily in the Biotechnology Research industry.

How many employees does Gilead HIV have ?

Gilead HIV employs approximately None employees people worldwide.

Does Gilead HIV own any subsidiaries ?

Gilead HIV presently has no subsidiaries across any sectors.

How many LinkedIn followers does Gilead HIV have ?

Gilead HIV's official LinkedIn profile has approximately 950 followers.

What is the NAICS classification code for Gilead HIV ?

Gilead HIV is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).

Does Gilead HIV have a Crunchbase profile ?

No, Gilead HIV does not have a profile on Crunchbase.

Does Gilead HIV have a LinkedIn profile ?

Yes, Gilead HIV maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/gilead-hiv.

How many cybersecurity incidents has Gilead HIV experienced ?

As of August 12, 2026, Rankiteo reports that Gilead HIV has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Gilead HIV have ?

Gilead HIV has an estimated 4,739 peer or competitor companies worldwide.

What types of cybersecurity incidents has Gilead HIV faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack and Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Gilead HIV

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Gilead HIV Vendor Cyber Rating & Cyber Score

gileadhiv.com

Add Your Compliance Badge

Decades of breakthrough science, bold partnerships, and tireless advocacy turned HIV from a fatal diagnosis to one that could be managed and prevented. We’re driving the next era of HIV innovation to support the wellness of all people impacted by it. Social Media Guidelines: https://www.gilead.com/social-media-guidelines This site is intended for US residents.

Gilead HIV A.I CyberSecurity Scoring

Scoring History

Gilead HIV

Gilead HIV CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Gilead HIV

Breach

2/2025

GIL957091725

Gilead HIV

Cyber Attack

05/2020

GIL1527222

Loading…

A.I.

Gilead HIV Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Gilead HIV

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Gilead HIV in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Gilead HIV in 2026.

Incident Types Gilead HIV vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Gilead HIV in 2026.

Incident History - Gilead HIV (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Gilead HIV Subsidiaries

Gilead HIV

Biotechnology Research

Website: https://www.gileadhiv.com/

Company Size: 10,001+ employees

Gilead Sciences ItaliaPharmaceutical Manufacturing

Gilead Sciences España y PortugalBiotechnology Research

Gilead SciencesBiotechnology Research

Gilead Sciences UK & IrelandBiotechnology Research

Gilead Sciences AustraliaBiotechnology Research

Loading…

Gilead HIV Similar Companies

CSL

cb csl.com

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

bioMérieux

biomerieux.com

A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.

ICON plc

iconplc.com

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

The National Institutes of Health

cb nih.gov

NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement

Fortrea

fortrea.com

Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com

Agilent Technologies

cb agilent.com

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

Gilead Sciences

cb gilead.com

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

Charles River Laboratories

criver.com

At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL

Loading…

NEWS

Gilead HIV CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 05, 2026 06:02 AM

South Africa seeks local production of Gilead's HIV prevention drug

South Africa is asking local drugmakers to start a process to make Gilead Sciences' long-acting HIV prevention drug, lenacapavir,...

Read Article

February 17, 2026 08:00 AM

Gilead’s HIV Advances And Yescarta Label Shift Refocus Investment Thesis

Gilead Sciences (NasdaqGS:GILD) plans to present late breaking data at CROI 2026 on a new investigational single tablet HIV regimen.

Read Article

February 13, 2026 08:00 AM

Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?

Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.

Read Article

January 12, 2026 08:00 AM

Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says

Gilead Sciences' new HIV prevention drug has been added to CVS Health's commercial insurance plans, the drugmaker's CEO Daniel O'Day said at...

Read Article

December 15, 2025 08:00 AM

Gilead’s HIV ART combo deemed non-inferior in second Phase III trial

Gilead Sciences' human immunodeficiency virus (HIV) single-tablet combination antiretroviral therapy (ART) has proven non-inferior to...

Read Article

December 15, 2025 08:00 AM

Gilead's experimental HIV treatment non-inferior to blockbuster drug in trial

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling drug Biktarvy in...

Read Article

December 07, 2025 08:00 AM

Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates

Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate...

Read Article

December 06, 2025 08:00 AM

Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences shares closed at $121.22 on December 5, 2025, about 6% below their 52-week high.

Read Article

November 19, 2025 08:00 AM

Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug Biktarvy in a...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-73250

SUMMARY

Notepad++ is a free and open-source source code editor. Prior to 8.9.7, the Notepad++ Windows 11 x64 and ARM64 installer passes the attacker-influenced installation directory `$INSTDIR` from PowerEditor/installer/nppSetup.nsi into a PowerShell `-Command` string used by RegisterMSIX to invoke Add-AppxPackage, allowing PowerShell subexpression syntax such as `$()` in the installation path to execute commands in the installer's security context when the context menu component is selected. This issue is fixed in version 8.9.7.

Published

Date2026-08-11

Updated

Date2026-08-11

RISK INFORMATION (Score: )

cvss4

Base Score: 5.4

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:L/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-73249

SUMMARY

calibre is an e-book manager. Prior to 9.12.0, the calibre Content Server endpoint POST /book-update-annotations/{library_id}/{book_id}/{fmt} in src/calibre/srv/books.py omits needs_db_write=True, causing Router.dispatch() to skip ctx.check_for_write_access() before update_annotations() passes attacker-controlled JSON to db.merge_annotations_for_book(), which allows a readonly user or an anonymous user on an unauthenticated deployment to persist unauthorized book annotation changes. This issue is fixed in version 9.12.0.

Published

Date2026-08-11

Updated

Date2026-08-11

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-73248

SUMMARY

calibre is an e-book manager. Prior to 9.12.0, calibre processes attacker-controlled composite_template metadata from a malicious EPUB, OPF, PDF, or similar file through program: and a nested template() call whose formatter does not inherit allow_python_templates=False, allowing a nested python: template to reach compile_python_template and execute arbitrary Python code when the file is opened or imported. This issue is fixed in version 9.12.0.

Published

Date2026-08-11

Updated

Date2026-08-11

RISK INFORMATION (Score: )

cvss4

Base Score: 8.5

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-73247

SUMMARY

Kestra is an open-source, event-driven orchestration platform. Prior to 2.0.0, Kestra's core/src/main/java/io/kestra/core/runners/pebble/functions/HttpFunction.java passes the user-controlled http() uri argument to URI.create() and the server-side HTTP client without restricting private, loopback, or link-local destinations, allowing an unauthenticated attacker to import and execute a flow that accesses internal services or cloud metadata.

Published

Date2026-08-11

Updated

Date2026-08-11

RISK INFORMATION (Score: 8.6)

cvss3

Base Score: 8.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:N/A:N

Impact Score

Exploitability

3.9

REFERENCES

https://github.com/kestra-io/kestra/security/advisories/GHSA-r56g-q4p6-m3p6

CVE-2026-73246

SUMMARY

Kestra is an open-source, event-driven orchestration platform. Prior to 2.0.0-rc6, Kestra's worker/src/main/java/io/kestra/worker/endpoint/WorkerEndpoint.java serves GET /worker without authentication and serializes the complete live Task object, which can expose commands, environment variables, HTTP headers, connection details, plaintext credentials, and execution identifiers while the main API on port 8080 remains protected. This issue is fixed in 2.0.0-rc6.

Published

Date2026-08-11

Updated

Date2026-08-11

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

3.9

REFERENCES

https://github.com/kestra-io/kestra/security/advisories/GHSA-m65f-q5gj-hg46

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…